

1     **Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme**  
2             **Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in**  
3                     **South Korea: A nationwide study**

4  
5     Ju Hwan Kim Pharm.D<sup>a,\*</sup>, Yeon-Hee Baek, B.A<sup>a,\*</sup>, Hyesung Lee M.S<sup>a</sup>, Young June Choe  
6             M.D, Ph.D<sup>b</sup>, Hyun Joon Shin M.D, Sc.D<sup>c</sup> Ju-Young Shin Ph.D<sup>a, d</sup>

7  
8     \*These authors contributed equally to this work as co-first authors

9  
10    <sup>a</sup> School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea

11    <sup>b</sup> Division of Infectious Diseases, Department of Social and Preventive Medicine, Hallym  
12    University College of Medicine, Chuncheon, Republic of Korea

13    <sup>c</sup> Department of Medicine, Brigham and Women's Hospital, Department of Global Health and  
14    Social Medicine, Harvard Medical School, Boston, Massachusetts, USA

15    <sup>d</sup> Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan  
16    University, Seoul, Republic of Korea

17  
18    **Short title:** ACEIs or ARBs use and COVID-19

19  
20    **Acknowledgement:** The authors appreciate healthcare professionals dedicated to treating  
21    COVID-19 patients in Korea, and the Ministry of Health and Welfare, the Health Insurance  
22    Review & Assessment Service, and Do-Yeon Cho of the Health Insurance Review &  
23    Assessment Service of South Korea for sharing invaluable national health insurance claims  
24    data in a prompt manner.

25    **Funding:** This study was supported by the Government-wide R&D Fund project for

26 infectious disease research through the Government-wide R&D Fund for Infectious Disease  
27 Research (GFID) funded by the Korea Health Industry Development Institute of Republic of  
28 Korea (No. HG18C0068).

29

30 **Disclosures:** Dr. JY Shin report receipt of research funding from the Ministry of Food and  
31 Drug Safety, Ministry of Health and Welfare, and National Research Foundation of Republic  
32 of Korea; grants from pharmaceutical companies including Amgen, Pfizer, Hoffmann-La  
33 Roche, Dong-A ST, Yungjin outside the submitted work.

34 No other disclosures were reported.

35

36 **Address for Correspondence:** Ju-Young Shin, PhD, Assistant Professor  
37 School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon,  
38 Gyeonggi-do 16419, Republic of Korea; E-mail: [shin.jy@skku.edu](mailto:shin.jy@skku.edu)

39 **Abstract**

40 There is ongoing debate as to whether angiotensin-converting enzyme inhibitors (ACEIs) or  
41 angiotensin-receptor blockers (ARBs) use is associated with poor prognosis of coronavirus  
42 disease-2019 (COVID-19). We sought to investigate the association between ACEI/ARB use  
43 and risk of poor clinical outcomes from COVID-19. We identified 1,290 patients with  
44 hypertension, of which 682 had recorded ACEI/ARB use and 608 without the use during 30  
45 days preceding the date of COVID-19 diagnosis in completely enumerated COVID-19 cohort  
46 in South Korea. Our primary endpoint was the clinical outcomes comprised of all-cause  
47 mortality, use of mechanical ventilation, intensive care unit (ICU) admission, and sepsis. We  
48 used inverse probability of treatment weighting (IPTW) to mitigate selection bias, and  
49 Poisson regression model to estimate the relative risks (RR) and 95% confidence intervals  
50 (CI) to compare outcomes in ACEI/ARB users with non-users. Compared to non-use,  
51 ACEI/ARB use was associated with lower clinical outcomes (IPTW adjusted RR, 0.60; 95%  
52 CI, 0.42-0.85;  $p=0.0046$ ). When assessed by individual outcomes, ACEI/ARB use was not  
53 associated with all-cause mortality (IPTW adjusted RR, 0.62; 95% CI, 0.35-1.09;  $p=0.0973$ )  
54 and respiratory events (IPTW adjusted RR, 0.99; 95% CI, 0.84-1.17;  $p=0.9043$ ). Subgroup  
55 analysis showed a trend toward protective role of ACEIs and ARBs against overall outcomes  
56 in men (IPTW adjusted RR, 0.84; 95% CI, 0.69-1.03;  $p\text{-for-interaction}=0.008$ ) and with pre-  
57 existing respiratory disease (IPTW adjusted RR, 0.74; 95% CI, 0.60-0.92;  $p\text{-for-}$   
58  $\text{interaction}=0.0023$ ). We present clinical evidence to support continuing ACE/ARB use in  
59 completely enumerated hypertensive COVID-19 cohort in South Korea.

60

61 **Keywords:** COVID-19; hypertension; angiotensin-converting enzyme inhibitors;  
62 angiotensin-receptor blockers.

## 63 **Introduction**

64           The rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute  
65 respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing pandemic, having infected  
66 >2,800,000 people over 213 countries as of April 28, 2020 <sup>1</sup>. Concerns have been raised  
67 regarding poor prognosis of COVID-19 associated with the use of angiotensin-converting  
68 enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) <sup>2</sup>. ACEIs and ARBs  
69 were shown to upregulate ACE2 expression and activity in several experimental studies <sup>3-5</sup>.  
70 Given that the binding of ACE2 and viral spike protein of SARS-CoV-2 allows coronavirus  
71 entry into host cells, it had been hypothesized that potential upregulation of ACE2 owing to  
72 use of ARBs leads to an increased risk of severe and fatal health outcomes <sup>2,6</sup>.

73           In theory, patients with hypertension being managed with ACEIs or ARBs could be  
74 at increased risk of COVID-19 since increased ACE2 by these drug classes may increase  
75 viral entry into cells. Alternatively, increased ACE2 had been recognized to counterbalance  
76 the pro-inflammatory and vasoconstrictive effect of ACE, mainly through conversion of  
77 angiotensin II (Ang II) to Ang-(1-7), a peptide with potential protective anti-inflammatory  
78 properties that counterbalances pro-inflammatory activity of Ang II <sup>7-9</sup>.

79           In view of these two opposing mechanistic hypotheses, demands for clinical research  
80 remain very high. To date, several observational studies claimed that the use of ACEI/ARB  
81 was not associated with increased all-cause mortality <sup>10-14</sup>. However, these studies were  
82 limited due to methodological issues in study design, with the former lacking causal  
83 relationship assessment and latter suffering from immortal time bias arising from  
84 misclassification of exposure period. Given the lack of robust population-based study  
85 assessing the association between the use of ACEI/ARB and sequelae of COVID-19, we  
86 analyzed completely enumerated hypertensive COVID-19 cohort in South Korea to assess  
87 whether the use of ACEIs and ARBs are associated with poor clinical outcomes from

88 COVID-19.

## 89 **Methods**

90 We retrieved healthcare database from the Health Insurance Review & Assessment  
91 Service of South Korea, which covers over 50 million entire South Korean population, from  
92 January 1, 2015 to April 8, 2020. We used completely enumerated database of 69,793  
93 subjects who underwent COVID-19 screening test in South Korea. The database contains  
94 both inpatient and outpatient prescriptions, demographic (age, sex, and insurance type) and  
95 clinical information on visit dates for hospitalization and ambulatory cares, procedures, and  
96 diagnosis records coded using Korea Standard Classification of Diseases, 7<sup>th</sup> revision (K  
97 CD-7), which is based on International Classification of Diseases, 10<sup>th</sup> revision (ICD-10).  
98 The overall agreement of diagnostic records of hypertension, stroke, and heart disease was  
99 93.73%, 98.80%, and 97.93%, respectively <sup>15</sup>.

100 We conducted a retrospective cohort study of ACEI/ARB use and adverse outcomes  
101 from COVID-19 among patients with hypertension. We identified patients with laboratory  
102 confirmed diagnosis of COVID-19 between December 1, 2019 and April 8, 2020. Diagnoses  
103 were made based on the diagnostic results from on reverse transcription polymerase chain  
104 reaction (RT-PCR) method targeting the RNA-dependent RNA polymerase (RdRP), N, and E  
105 genes as recommended by the interim guidance of World Health Organization <sup>16</sup>. Cohort  
106 entry was defined as the date of incident diagnosis of COVID-19. We required patients to  
107 have a recorded diagnosis of hypertension within a 5-year lookback period from the cohort  
108 entry.

109 Exposure to ACEIs and ARBs was ascertained within 30 days preceding the cohort  
110 entry. Our exposure of interest was patients ever prescribed with ACEIs or ARBs either as a  
111 monotherapy or combination therapy. Non-users were those who had no prescription record  
112 of either ACEIs or ARBs during the exposure ascertainment period.

113 Our study outcomes included clinical outcomes indicative of poor prognosis for  
114 COVID-19, comprised of all-cause mortality, use of mechanical ventilation, intensive care  
115 unit (ICU) admission, or sepsis. We also assessed all-cause mortality and respiratory events  
116 (acute respiratory distress syndrome, interstitial lung disease, pneumonia, and respiratory  
117 failure) individually as the secondary endpoints. Each patient was followed until the  
118 occurrence of outcome of interest or data-censoring date.

119 We assessed baseline characteristics within 1 year before cohort entry. To make  
120 propensity score we used baseline confounders which include age at cohort entry, sex,  
121 income level, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, medical history (including diabetes, cardiovascular  
122 disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease,  
123 chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including  
124 other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha  
125 blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-  
126 lowering agents, and antianginal agents), dialysis, and the duration of hypertension (<1 year,  
127  $\geq 1$  year and <3 years,  $\geq 3$  years and <5 years, and  $\geq 5$  years). The treatments for COVID-19  
128 (including antibiotics, antivirals, antimalarials (chloroquine and hydroxychloroquine),  
129 corticosteroids, and intravenous immunoglobulin) were assessed but not included in the  
130 propensity score model as they act as the intermediates between exposure and outcome of our  
131 study.

132 We estimated propensity scores for receiving ACEIs or ARBs by fitting a  
133 multivariable logistic regression model using all pre-defined covariates assessed 1 year  
134 before cohort entry. We used inverse probability of treatment weighting (IPTW) based on the  
135 propensity scores to mitigate selection bias by the characteristics between ACEI/ARB users  
136 and non-users. IPTW creates a pseudo population, where the weighted exposure and  
137 comparator groups are representative of the patient characteristics in the overall population,

138 and thus generates the population average treatment effect<sup>17</sup>. We summarized baseline  
139 characteristics of the study cohort using counts and proportions or mean for categorical or  
140 continuous variables, respectively. We used Poisson regression model to estimate relative  
141 risk (RR) and corresponding 95% confidence intervals (CI) of each outcome in ACEI/ARB  
142 users compared to non-users in patients with COVID-19. The unweighted model was  
143 adjusted for pre-defined covariates including age, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, diabetes,  
144 CVD, and baseline respiratory diseases for parsimony. These covariates were also used in the  
145 IPTW weighted models for doubly robust estimation of causal effect. We chose adjusted  
146 IPTW weighted model as a main model to report the RRs and corresponding 95% CIs for the  
147 clinical outcomes in ACEI/ARB users, compared with non-user.

148         Given that ACEIs and ARBs, apart from hypertension, are primarily prescribed for  
149 patients with diabetes and CVD, we repeated analysis with the restricted cohort of patients  
150 with these health conditions to exclude confounding by indication. To evaluate whether the  
151 association differed by underlying patients' conditions, we conducted additional subgroup  
152 analysis using the interaction terms by age group, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, pre-existing  
153 respiratory disease, and hospitalization after diagnosis of COVID-19. In subgroup analysis,  
154 we used overall outcomes which include all-cause mortality, use of mechanical ventilation,  
155 ICU admission, sepsis, or the occurrence of respiratory events to increase the statistical  
156 power. Additionally, we conducted sensitivity analysis where we redefined exposure  
157 assessment window as within 180 days preceding the cohort entry to address potential  
158 exposure misclassification.

159         Our study complies with the Declaration of Helsinki and the study protocol was  
160 approved by the Institutional Review Board (IRB) of Sungkyunkwan University (SKKU  
161 2020-03-021) and obtaining informed consent was waived by the IRB.

## 162 **Results**

163           Among 5,707 patients with confirmed diagnosis of COVID-19, there were 1,290  
164 patients with past medical history of hypertension, of which 682 had recorded use of  
165 ACEI/ARB and 608 without the use during 30 days preceding cohort entry (**Figure 1**). The  
166 characteristics of the ACEI/ARB users compared with non-users are described in Table 1.  
167 Compared to non-users, ACEI/ARB users were older (mean age (standard deviation) 62.8  
168 years (14.4) vs. 61.3 years (16.6)), had higher proportion of men (53.4% vs. 49.8%), higher  
169 prevalence of hyperlipidemia (38.6% vs. 33.6%), diabetes (37.0% vs. 25.7%), CVD (27.9%  
170 vs. 26.0%), chronic kidney disease (18.8% vs. 15.6%) and duration of hypertension over 5  
171 years (56.7% vs. 41.5%). Concomitant use of other anti-hypertensives was generally similar  
172 between ACEI/ARB users and non-users, while the mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was higher  
173 in ACEI/ARB users (2.7 vs. 2.4).

174           During the study period, there were 23 (3.4%) and 28 (4.6%) cases of clinical  
175 outcomes in ACEI/ARB users and non-users, respectively (**Table 2**). Compared to non-use,  
176 ACEI/ARB use was associated with lower clinical outcomes that included all-cause mortality,  
177 mechanical ventilation, ICU admission, and sepsis (IPTW adjusted RR, 0.60; 95% CI, 0.42-  
178 0.85; p=0.0046). When assessed by individual outcome event, ACEI/ARB use was not  
179 associated with the risk of all-cause mortality (IPTW adjusted RR, 0.62; 95% CI, 0.35-1.09;  
180 p=0.0973) and respiratory events (IPTW adjusted RR, 0.99; 95% CI, 0.84-1.17; p=0.9043)  
181 compared with non-use.

182           We conducted sensitivity analysis where we redefined the exposure risk window as  
183 180 days preceding the cohort entry to account for potential exposure misclassification  
184 (**Table 3**). There were 28 (3.7%) and 23 (4.4%) cases of adverse outcomes in ACEI/ARB  
185 users and non-users, respectively. The results from sensitivity analysis were generally  
186 consistent with the main analysis; ACEI/ARB use was associated with lower clinical  
187 outcomes (IPTW adjusted RR, 0.65; 95% CI, 0.46-0.90; p=0.0094), all-cause mortality



188 (IPTW adjusted RR, 0.41; 95% CI, 0.25-0.68;  $p=0.0006$ ), but was not associated with  
189 respiratory events (IPTW adjusted RR, 0.94; 95% CI, 0.81-1.09;  $p=0.4188$ ) compared with  
190 non-use.

191 Subgroup analysis on the risk of clinical outcomes compared with non-use is  
192 presented in **Figure 2**. When assessed by exposure subtypes, no significant interaction  
193 between the subtypes and the overall outcomes was found ( $p$  for interaction= $0.015$ ); ACEI  
194 (IPTW adjusted RR, 0.67; 95% CI, 0.42-1.06) and ARB use (IPTW adjusted RR, 0.97; 95%  
195 CI, 0.83-1.13) was not associated with the risk of overall adverse outcomes. Interestingly,  
196 interaction-term analysis showed a trend toward protective role of ACEIs and ARBs against  
197 overall outcomes in men (IPTW adjusted RR, 0.84; 95% CI, 0.69-1.03;  $p$  for  
198 interaction= $0.008$ ), with pre-existing respiratory disease (IPTW adjusted RR, 0.74; 95% CI,  
199 0.60-0.92;  $p$  for interaction= $0.0023$ ) and in patients hospitalized for COVID-19 (IPTW  
200 adjusted RR, 0.93; 95% CI, 0.78-1.10;  $p$  for interaction $<0.0001$ ).

## 201 **Discussion**

202 To the best of our knowledge, this retrospective cohort study provides the first  
203 completely enumerated hypertensive COVID-19 cohort study in a national scale. We used  
204 medical claims data of patients diagnosed with COVID-19 in South Korea to demonstrate  
205 that ACEI/ARB use was not associated with poor clinical outcomes from COVID-19 among  
206 patients with hypertension. Specifically, ACEI/ARB use, compared with non-use, was  
207 associated with lower clinical outcomes that comprised of all-cause mortality, use of  
208 mechanical ventilation, ICU admission, and sepsis. To account for exposure misclassification,  
209 we conducted sensitivity analysis to assess exposure status during a period of 180 days  
210 preceding the cohort entry in which the IPTW adjusted RRs were largely consistent with the  
211 findings from main analysis across all outcome measures. Furthermore, the results from  
212 subgroup analysis accounting for potential confounding by indication also remained largely

213 consistent with the findings from main analysis.

214 While the underlying pathogenic link between hypertension and COVID-19 remains  
215 to be elucidated, concerns have been raised that ACEIs and ARBs, mainstay of therapy for  
216 hypertension and diabetes, may contribute to the adverse outcomes observed in COVID-19  
217 patients<sup>2</sup>. Indeed, interaction between SARS-CoV-2 and ACE2 was proposed a potential  
218 mechanism for COVID-19's cell entry<sup>18</sup>, and administration of ACEIs and ARBs  
219 upregulated ACE2 expression and activity in several experimental studies<sup>3-5</sup>, which may  
220 theoretically predispose patients on ACEIs or ARBs at greater risk of COVID-19. Conversely,  
221 beneficial role of ACE2 in COVID-19 had been reported, of which a recent pilot clinical trial  
222 in acute respiratory distress syndrome demonstrated the promising role of recombinant  
223 human ACE2 in attenuating the acute lung injury<sup>19</sup>. Moreover, experimental evidence  
224 indicates that ARBs, specifically losartan, restored the expression level of ACE2 which was  
225 downregulated in pre-clinical models of experimental SARS-CoV infection and acute lung  
226 injury<sup>3,20,21</sup>. While there is an ongoing debate on whether to continue or halt ACEI/ARB in  
227 COVID-19 patients with hypertension, real-world data from our study complement the  
228 position statements made by the medical societies such as European Society of Cardiology  
229 council, American College of Cardiology, American Heart Association, and Heart Failure  
230 Society of America on continuing the use of ACEIs or ARBs as prescribed<sup>22,23</sup>, as  
231 ACEI/ARB use was not associated with poor clinical outcomes from COVID-19.

232 Consistent with our study finding, several recently published studies also have  
233 demonstrated no harm or even protective role of ACEI/ARB in COVID-19. A study in Italy  
234 utilized case-control design that involved 6,272 COVID-19 cases and 30,579 matched  
235 controls to report that ACEI/ARB use was not associated with the risk of COVID-19  
236 (adjusted OR, 0.95; 95% CI, 0.86-1.05)<sup>13</sup>. The most recent single tertiary center-based study  
237 in the United States also reported null association between ACEI/ARB use and poor

238 outcomes from COVID-19 among 2,573 hypertensive COVID-19 patients, with the median  
239 difference in percentage points between ACEI/ARB users and non-users of -0.5% (95% CI, -  
240 4.3-3.2)<sup>14</sup>. Although methodological issues inherent in observational studies limit the  
241 interpretation of the study findings, study conclusions of these recently published studies are  
242 consistent with the findings of our study, and provide clinical evidence that ACEI/ARB use,  
243 at least, are not associated with increased risk of poor clinical outcomes from COVID-19. In  
244 addition to the observed protective role of ACEIs and ARBs during COVID-19, our subgroup  
245 analysis showed a greater benefit with regard to clinical outcomes from COVID-19 in  
246 association with ACEI/ARB use than with non-use in men, with pre-existing respiratory  
247 disease, and in patients hospitalized for COVID-19. These subgroups had been reported to  
248 have poor prognosis in COVID-19<sup>13</sup>, and our study findings should be interpreted with  
249 caution as we used overall outcomes to increase the statistical power in assessing the role of  
250 ACEI/ARB among these subgroups. Additional aspect to be noted in our subgroup analysis is  
251 that proportion of patients taking ARBs were notably higher compared with ACEIs as  
252 regional hypertension management guideline in Korea recommended ARBs over ACEIs due  
253 to more favorable adherence and less frequent adverse events<sup>24</sup>.

254 Our study provided clinical evidence indicating ACEI/ARB use not associated with  
255 poor prognosis of COVID-19. We generated practicable evidence which addresses the urgent  
256 public health need in the uncertainty of clinical consequences of ACEI/ARB use among  
257 patients with COVID-19. Second, our results have a solid external validity by assembling  
258 completely enumerated COVID-19 cases that occurred in South Korea. South Korea have  
259 implemented rigorous screening, contact tracing and quarantine measures, conducting a total  
260 of 601,660 COVID-19 screening tests as of April 27 to proactively contain COVID-19<sup>25</sup>. All  
261 individuals with epidemiologic links with suspected or confirmed COVID-19 patients or  
262 came from abroad have been self-quarantined for 14 days, and those who developed a fever

263 (37.5°C and above) or respiratory symptoms received COVID-19 screening tests <sup>26</sup>; thus,  
264 underdiagnosis of COVID-19 is likely to be minimal. Third, our study results were consistent  
265 in the subgroup analysis by pre-existing diabetes or CVD, which suggests the robustness of  
266 our results from confounding by indication given that ACEIs and ARBs are primarily  
267 prescribed for patients with these coexisting comorbidities.

268 Our study also has some limitations. First, potential misclassification of diagnosis-  
269 based outcomes (sepsis and respiratory events) may present. Nevertheless, a validation study  
270 comparing diagnoses in the South Korean healthcare database with electronic medical  
271 records reported an overall positive predictive value of 82% <sup>27</sup>. Death records and procedure  
272 codes including mechanical ventilation and ICU admission have high validity, and thus less  
273 likely to affect our study conclusion. Second, there is a potential exposure misclassification  
274 owing to short exposure ascertainment period. We found consistent result with the main  
275 analysis when the exposure risk window was redefined as 180 days. Third, residual  
276 confounding from unmeasured confounders (e.g. smoking history, body mass index, baseline  
277 blood pressure and laboratory test results) may have affected our results given inherent  
278 limitation of available variables in the analysis of health claims data. Finally, we included  
279 prevalent users of ACEI/ARB, while ideally new-user design is recommended where all  
280 study subjects are naïve to previous use of ACEI/ARB to address potential under  
281 ascertainment of events that occur early in therapy and to precisely control for confounders  
282 that may be altered by the study drug <sup>28</sup>. However, we used a prevalent user cohort of  
283 ACEI/ARB given that a new-user design would exclude the large number of subjects that  
284 may represent clinically relevant subset.

285 In conclusion, our study findings did not identify increased risk of adverse outcomes  
286 with the use of ACEIs or ARBs among COVID-19 patients with hypertension. We present

287 clinical evidence to support current medical societies recommendation on continuing ACEIs  
288 or ARBs as prescribed in COVID-19 patients.



## References

1. World Health Organization Coronavirus disease (COVID-19) Situation Dashboard. World Health Organization: World Health Organization, 2020.
2. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nature reviews Cardiology* 2020.
3. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* 2005;111:2605-2610.
4. Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, Hoffman A, Abassi Z. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. *Am J Physiol Heart Circ Physiol* 2005;289:H1351-1358.
5. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension* 2004;43:970-976.
6. Lia Y CX, Zeng Q, Chen Z, Wang Z, Yuan J, Wang X, Zhou Z, Wei Y, Cao G. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province. *J Clin Cardiol* 2020;36:201-203.
7. Rodrigues Prestes TR, Rocha NP, Miranda AS, Teixeira AL, Simoes ESAC. The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research. *Curr Drug Targets* 2017;18:1301-1313.
8. Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT(2) receptor and tissue injury: therapeutic implications. *Curr Hypertens Rep* 2014;16:416.

9. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. *BMJ* 2020;369:m1313.
10. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020.
11. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res* 2020.
12. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect* 2020;9:757-760.
13. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med* 2020.
14. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med* 2020.
15. Kim YY, Park JH, Kang HJ, Lee EJ, Ha S, Shin SA. Level of Agreement and Factors Associated With Discrepancies Between Nationwide Medical History Questionnaires and Hospital Claims Data. *J Prev Med Public Health* 2017;50:294-302.



16. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020: World Health Organization, 2020.
17. Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. *Circulation Cardiovascular quality and outcomes* 2013;6:604-611.
18. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020;181:281-292 e286.
19. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit Care* 2017;21:234.
20. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005;11:875-879.
21. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005;436:112-116.
22. Position statement of the ESC Council on Hypertension on ACE-inhibitors and anigotensin receptor blockers. European Society of Cardiology, 2020.
23. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. American Heart Association, 2020.
24. Kim SH, Shin DW, Kim S, Han K, Park SH, Kim YH, Jeon SA, Kwon YC. Prescribing

Patterns of Antihypertensives for Treatment-Naive Patients in South Korea: From Korean NHISS Claim Data. *Int J Hypertens* 2019;2019:4735876.

**25.** Coronavirus Disease-19, Republic of Korea. Central Disaster Management Headquarters: Ministry of health and welfare, Republic of Korea, 2020.

**26.** Tackling COVID-19—Health, Quarantine and Economic Measures: Korean Experience. Ministry of Economy and Finance, Republic of Korea, 2020.

**27.** Screening for osteoporosis: U.S. preventive services task force recommendation statement. *Annals of internal medicine* 2011;154:356-364.

**28.** Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *American journal of epidemiology* 2003;158:915-920.

**Table 1.** Characteristics of ACEI/ARB users and non-users in hypertensive COVID-19 patients

Characteristics	Overall Cohort (n=1,290)	ACEI/ARB use (n=682)	Non-use (n=608)
<b>Age years, mean (SD)</b>	62.1 (15.5)	62.8 (14.4)	61.3 (16.6)
<40	114 (8.8)	42 (6.2)	72 (11.8)
40-64	582 (45.1)	325 (46.7)	257 (42.3)
65-84	517 (40.1)	273 (40.0)	244 (40.1)
≥85	77 (6.0)	42 (6.2)	35 (5.8)
<b>Male, N (%)</b>	667 (51.7)	364 (53.4)	303 (49.8)
<b>Medical History, N (%)</b>			
Hyperlipidemia	467 (36.2)	263 (38.6)	204 (33.6)
Diabetes	408 (31.6)	252 (37.0)	156 (25.7)
Cancer	138 (10.7)	62 (9.1)	76 (12.5)
<b>Respiratory disease</b>	432 (33.5)	222 (32.6)	210 (34.5)
Asthma	132 (10.2)	59 (8.7)	73 (12.0)
COPD	283 (21.9)	137 (20.1)	146 (24.0)
Bronchiectasis	15 (1.2)	10 (1.5)	5 (0.8)
Pneumonia	143 (11.1)	83 (12.2)	60 (9.9)
Interstitial lung disease	16 (1.24)	8 (1.2)	8 (1.3)
<b>Cardiovascular disease</b>	348 (27.0)	190 (27.9)	158 (26.0)
Peripheral vascular disease	113 (8.8)	64 (9.4)	49 (8.1)
Coronary artery disease	150 (11.6)	72 (10.6)	78 (12.8)
Atrial fibrillation	40 (3.1)	19 (2.8)	21 (3.5)
Valvular heart disease	10 (0.8)	8 (1.2)	2 (0.3)
Heart failure	100 (7.8)	59 (8.7)	41 (6.7)
Arrhythmia	38 (3.0)	18 (2.6)	20 (3.3)
Chronic kidney disease	223 (17.3)	128 (18.8)	95 (15.6)
Chronic liver disease	164 (12.7)	80 (11.7)	84 (13.8)
Stroke	137 (10.6)	63 (9.2)	74 (12.2)
Other cerebrovascular diseases	87 (6.7)	44 (6.5)	43 (7.1)
<b>Comedications, N (%)</b>			
CCBs	476 (36.9)	228 (33.4)	248 (40.8)
Diuretics	282 (21.9)	149 (21.9)	133 (21.9)
β-blockers	368 (28.5)	182 (26.7)	186 (30.6)
Alpha blockers	187 (14.5)	106 (15.5)	81 (13.3)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc score, mean (SD)</b>	2.5 (1.6)	2.7 (1.4)	2.4 (1.7)
0-1	371 (28.8)	148 (21.7)	223 (36.7)
2-5	860 (66.7)	507 (74.3)	353 (58.1)
6-9	59 (4.6)	27 (4.0)	32 (5.3)
<b>Duration of hypertension, N (%)</b>			
<1 year	114 (8.8)	40 (5.9)	74 (12.2)
≥1 year and <3 years	247 (19.2)	106 (15.5)	141 (23.2)
≥3 years and <5 years	290 (22.5)	149 (21.9)	141 (23.2)
≥5 years	639 (49.5)	387 (56.7)	252 (41.5)

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019; SD, standard deviation; COPD, chronic obstructive pulmonary disease; CCBs, calcium channel blockers.



**Table 2.** Relative risks of clinical outcomes in ACEI/ARB users compared to non-users in in hypertensive COVID-19 patients

	No. of patients	No. of events	Event rate (%)	Unweighted model		IPTW weighted model*	
				Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)	Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)
<b>All-cause mortality, mechanical ventilation, ICU admission, sepsis</b>							
Non-use	608	28	4.6	1.00	1.00	1.00	1.00
ACEIs or ARBs use	682	23	3.4	0.73 (0.42-1.27)	0.71 (0.41-1.24)	0.60 (0.42-0.85)	0.60 (0.42-0.85) <sup>§</sup>
<b>All-cause mortality</b>							
Non-use	608	12	2.0	1.00	1.00	1.00	1.00
ACEIs or ARBs use	682	10	1.5	0.74 (0.32-1.72)	0.71 (0.31-1.67)	0.64 (0.37-1.12)	0.62 (0.35-1.09)
<b>Respiratory events<sup>‡</sup></b>							
Non-use	608	108	17.8	1.00	1.00	1.00	1.00
ACEIs or ARBs use	682	126	18.5	1.04 (0.80-1.35)	1.02 (0.79-1.32)	0.99 (0.84-1.16)	0.99 (0.84-1.17)

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019; IPTW, inverse probability of treatment weighting; RR, relative risk; CI, confidence interval; ICU, intensive care unit.

\*To make IPTW, age at cohort entry, sex, income level, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years, and  $\geq$ 5 years) were used.

<sup>†</sup>For adjusted RR, multivariable Poisson regression was used and adjusted for age, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, diabetes, cardiovascular disease, and respiratory disease.

<sup>‡</sup>Respiratory events include acute respiratory distress syndrome, interstitial lung disease, pneumonia, and respiratory failure.

<sup>§</sup>p-value <0.05

**Table 3.** Sensitivity analysis with redefined exposure risk window of 180 days preceding the cohort entry for the relative risks of clinical outcomes in ACEI/ARB users compared to non-users in hypertensive COVID-19 patients

	No. of patients	No. of events	Event rate (%)	Unweighted model		IPTW weighted model*	
				Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)	Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)
<b>All-cause mortality, mechanical ventilation, ICU admission, sepsis</b>							
Non-use	523	23	4.4	1.00	1.00	1.00	1.00
ACEIs or ARBs use	767	28	3.7	0.83 (0.48-1.44)	0.79 (0.45-1.38)	0.68 (0.49-0.94) <sup>§</sup>	0.65 (0.46-0.90) <sup>§</sup>
<b>All-cause mortality</b>							
Non-use	523	12	2.3	1.00	1.00	1.00	1.00
ACEIs or ARBs use	767	10	1.3	0.57 (0.25-1.32)	0.52 (0.22-1.22)	0.45 (0.27-0.74) <sup>§</sup>	0.41 (0.25-0.68) <sup>§</sup>
<b>Respiratory events<sup>‡</sup></b>							
Non-use	523	92	17.6	1.00	1.00	1.00	1.00
ACEIs or ARBs use	767	142	18.5	1.05 (0.81-1.37)	1.08 (0.77-1.32)	0.98 (0.84-1.13)	0.94 (0.81-1.09)

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019; IPTW, inverse probability of treatment weighting; RR, relative risk; CI, confidence interval; ICU, intensive care unit.

\*To make IPTW, age at cohort entry, sex, income level, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years, and  $\geq$ 5 years) were used.

<sup>†</sup>For adjusted RR, multivariable Poisson regression was used and adjusted for age, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, diabetes, cardiovascular disease, and respiratory disease.

<sup>‡</sup>Respiratory events include acute respiratory distress syndrome, interstitial lung disease, pneumonia, and respiratory failure.

<sup>§</sup>p-value <0.05

## Figure legends

**Figure 1.** Description of data source and selection of hypertensive COVID-19 cohort

Abbreviations: HIRA, Health Insurance Review & Assessment Service; COVID-19, coronavirus disease 2019; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

**Figure 2.** Relative risks (95% confidence intervals) of overall adverse outcomes in ACEI/ARB users compared to non-users in selected population subgroups


Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; IPTW, inverse probability of treatment weighting; CI, confidence interval

\*Overall outcomes include all-cause mortality, use of mechanical ventilation, admission to intensive care unit, sepsis, or the occurrence of respiratory events.

† Relative risks were adjusted for age, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, diabetes, cardiovascular disease, and respiratory disease.

‡ To make IPTW, age at cohort entry, sex, income level, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and the duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years, and  $\geq$ 5 years).

**Figure 1.** Description of data source and selection of hypertensive COVID-19 cohort



Abbreviations: HIRA, Health Insurance Review & Assessment Service; COVID-19, coronavirus disease 2019; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.



**Figure 2.** Relative risks (95% confidence intervals) of overall clinical outcomes\* in

ACEI/ARB users compared to non-users in selected population subgroups

Characteristics	No. of patients	Event rates		IPTW weighted relative risks (95% CI) <sup>†</sup>	p
		ACEI/ARB	Non-user		
<b>Age group</b>					
-39	114	2.38	8.33	0.32 (0.07-1.41)	0.13
40-64	582	14.46	13.23	1.33 (1.00-1.78)	0.05
65-84	517	26.37	27.46	0.85 (0.69-1.05)	0.14
≥85	77	40.48	40.00	0.96 (0.61-1.50)	0.86
<i>p</i> for interaction				0.3209	
<b>Sex</b>					
Male	667	19.23	23.76	0.84 (0.69-1.03)	0.09
Female	623	21.07	16.07	1.14 (0.90-1.44)	0.29
<i>p</i> for interaction				0.008	
<b>Drug subtypes<sup>‡</sup></b>					
ARBs	642	20.4	19.90	0.97 (0.83-1.13)	0.67
ACEIs	37	16.22	19.90	0.67 (0.42-1.06)	0.09
<i>p</i> for interaction				0.1524	
<b>CHA2DS2-VASc score</b>					
0-1	371	12.84	13.45	0.86 (0.56-1.31)	0.48
2-5	860	21.10	23.51	0.95 (0.80-1.13)	0.54
6-9	59	40.74	25.00	1.39 (0.74-2.64)	0.31
<i>p</i> for interaction				0.6854	
<b>Pre-existing diabetes or CVD</b>					
Yes	621	22.07	20.87	1.07 (0.87-1.33)	0.52
No	669	17.78	19.21	0.83 (0.66-1.04)	0.11
<i>p</i> for interaction				0.1344	
<b>Pre-existing respiratory disease</b>					
Yes	432	26.58	31.42	0.74 (0.60-0.92)	0.01
No	858	16.96	13.82	1.23 (0.98-1.53)	0.07
<i>p</i> for interaction				0.0023	
<b>Hospitalization for COVID-19</b>					
Yes	612	34.15	34.15	0.93 (0.78-1.10)	0.40
No	678	7.28	7.17	1.05 (0.73-1.50)	0.80
<i>p</i> for interaction				<.0001	

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II

receptor blockers; IPTW, inverse probability of treatment weighting; CI, confidence interval

\*Overall clinical outcomes include all-cause mortality, use of mechanical ventilation, admission to intensive care unit, sepsis, or the occurrence of respiratory events.

<sup>†</sup>Relative risks were adjusted for age, sex, CHA2DS2-VASc score, diabetes, cardiovascular

disease, and respiratory disease.

‡To make IPTW, age at cohort entry, sex, income level, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and the duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years, and  $\geq$ 5 years).